The impact of catecholamines in patients with or without beta-blockers on the ventricular fibrillation cycle length and ventricular fibrillation cycle length variability

Annals of Noninvasive Electrocardiology

Volumn 10, Issue 3, 2005, Pages 305-311

  Min, Bokyung ^b   Kluger, Jeffrey ^b   Kalus, James S ^b   Guertin, Danette ^b   McBride, Brian F ^b   White, C Michael ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b NONE

Author keywords

Implantable defibrillators; Variability of VFCL; Ventricular arrhythmias; VFCL

Indexed keywords

ADRENALIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NORADRENALIN; PLACEBO;

ADULT; AGED; ARTICLE; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFIBRILLATOR; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INFUSION; DRUG USE; FEMALE; HEART CYCLE; HEART ELECTROPHYSIOLOGY; HEART RATE VARIABILITY; HEART VENTRICLE FIBRILLATION; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; AGED; ANALYSIS OF VARIANCE; DEFIBRILLATORS, IMPLANTABLE; DOUBLE-BLIND METHOD; EPINEPHRINE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NOREPINEPHRINE; TREATMENT OUTCOME; VENTRICULAR FIBRILLATION;

EID: 23844441263     PISSN: 1082720X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1542-474X.2005.00631.x     Document Type: Article

References (13)

1. Opthof T, Misier ARR, Coronael R, et al. Dispersion of refractoriness in canine ventricular myocardium: Effects of sympathetic stimulation. Circ Res 1991;68:1204-1215.
2. Pogwizd SM, Corr PB. Mechanisms underlying the development of ventricular fibrillation during early myocardial ischemia. Circ Res 1990;66:672-695.
3. Yokoshiki H, Kohya T, Sato M, et al. Increased cycle length variability during ventricular fibrillation: A novel predictor of arrhythmia recurrence. J Electrocardiol 2003;36:137-146.
4. Makikallio TH, Huikuri HV, Myerburg RJ, et al. Differences in the activation patterns between sustained and self-terminating episodes of human ventricular fibrillation. Ann Med 2002;34:130-135.
5. Dorian P, Newman D. Effect of sotalol on ventricular fibrillation and defibrillation in humans. Am J Cardiol 1993;72:72A-79A.
6. Swartz JF, Jones JL, Fletcher RD. Characterization on ventricular fibrillation based on monophasic action potential morphology in the human heart. Circulation 1993;87:1907-1914.
7. Omichi C, Zhou S, Lee MH, et al. Effects of amiodarone on wave front dynamics during ventricular fibrillation in isolated swine right ventricle. Am J Physiol Heart Circ Physiol 2002;282:H1063-H1070.
8. Huang J, Skinner JL, Rogers JM, et al. The effects of acute and chronic amiodarone on activation patterns and defibrillation threshold during ventricular fibrillation in dogs. J Am Coll Cardiol 2002;40:375-383.
9. Qi X, Varma P, Newman D, et al. Gap junction blockers decrease defibrillation thresholds without changes in ventricular refractoriness in isolated rabbit hearts. Circulation 2001;104:1544-1549.
10. Sims JJ, Winecoff AP, Ujhelyi MR. Lidocaine does not affect myocardial electrical heterogeneity: Implications for low proarrhythmic actions. Pharmacotherapy 1997;17:1267-1273.
11. Suddath WO, Deychak Y, Varghese PJ. Electrophysiologic basis by which epinephrine facilitates defibrillation after prolonged episodes of ventricular fibrillation. Ann Emerg Med 2001;38:201-206.
12. Tovar OH, Bransford PP, Jones JL. Probability of induction and stabilization of ventricular fibrillation with epinephrine. J Mol Cell Cardiol 1998;30:373-382.
13. Tovar OH, Jones JL. Electrophysiological deterioration during long-duration ventricular fibrillation. Circulation 2000;102:2886-2891.